Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-150-2 | CAS number: 2643-07-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The oral administration of N-Chlorethyl,N-Ethyl-4-Aminobenzaldehyde by gavage over a period of 4 weeks caused incipient signs of general systemic toxicity at dose levels of 10 mg/kg bw/d in female animals (clinicochemical parameters) and 40 mg/kg bw/d in both genders. Therefore, the NOAEL was 2.5 mg/kg bw/d in female and 10 mg/kg bw/d in male Wistar rats.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 2.5 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
A repeated dose 28-day toxicity study in Wistar rats according to OECD TG 407 in compliance with GLP was assigned as key study for short-term repeated dose toxicity (BASF SE, 2010). In this study, the test substance was administered for 4 weeks daily by gavage to male and female Wistar rats at dose levels of 2.5, 10 and 40 mg/kg bw/d (test groups 1-3).
Regarding clinical examinations, signs of general systemic toxicity were only observed at a dose level of 40 mg/kg bw/d as there were lower body weights in male animals at the end of the study accompanied with reduced body weight gain. In addition, food consumption was slightly lower during the second half of the administration period. In male animals of test groups 1 and 2 (2.5 and 10 mg/kg bw/d) as well as in female animals of all test groups no impairment of these parameters were observed during clinical examinations. Salivation was seen after dosing nearly all rats of test group 3 (40 mg/kg bw/d) and. From the temporary, short appearance immediately after dosing it is likely, that this finding was induced by a bad taste of the test substance or local affection of the upper digestive tract. This finding was not considered to be an adverse and toxicologically relevant effect. All other clinical parameters as well as FOB and MA did not reveal any treatment-related effects.
Regarding clinical pathology, the common alteration in rats of both sexes of test group 3 (40 mg/kg bw/d) was the decrease of globulin levels. This may include globulin transport proteins because their reduction led to decreased calcium levels in females of test groups 2 and 3 (10 and 40 mg/kg bw/d) and to decreased cholesterol and triglyceride levels in males of test group 3 (40 mg/kg bw/d). The reduced creatinine levels in combination with the decreased globulin levels in females might be due to a decreased formation of skeletal muscles. The reason for the higher potassium levels in males of the test group 3 (40 mg/kg bw/d) could not be elucidated, but a compound-related effect could not be excluded.
Regarding pathology, males and females of test group 3 (40 mg/kg bw/d) showed a decrease in terminal body weight, which was regarded to be a treatment-related effect. In addition, significant increases of absolute and relative liver weights were observed in females of this test group but no histopathological correlate was found for the liver weight increase. Therefore, a treatment-related effect cannot be completely ruled out.
In conclusion, the oral administration of N-Chlorethyl,N-Ethyl-4-Aminobenzaldehyde by gavage over a period of 4 weeks caused incipient signs of general systemic toxicity at dose levels of 10 mg/kg bw/d in female animals (clinicochemical parameters) and 40 mg/kg bw/d in both genders. Therefore, the NOAEL was determined to be 2.5 mg/kg bw/d in female and 10 mg/kg bw/d in male Wistar rats.
Justification for classification or non-classification
EU classification according to Annex VI of the Directive 67/548/EEC:
- Toxic: Danger of serious damage to health by prolonged exposure if swallowed, R48/25
GHS classification according toAnnex I 1272/2008 CLP (EU GHS):
- STOT repeated Cat. 1
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.